Boron

Clinical Summary

Boron is a trace metalloid (atomic number 5) obtained entirely from diet — fruits, nuts, legumes, wine. The body does not synthesize it. After ingestion, all forms hydrolyze to boric acid (H₃BO₃), which is absorbed at 85–90% via passive diffusion and excreted renally (>90%). No significant hepatic metabolism. Homeostasis maintained through renal excretion adjustment. Plasma reference: 34–95 ng/mL. Bone concentrations: 3–10 ppm.

Why it matters: Boron modulates steroid hormone metabolism (Vitamin D3, estrogen, testosterone), reduces inflammatory cytokines (CRP 23–88%, TNF-α, IL-6), supports calcium/magnesium retention, and influences osteoblast/osteoclast activity. Average US dietary intake (0.87–1.35 mg/day) may be suboptimal for therapeutic effects requiring 3–6 mg/day.

Who benefits most: Adults with osteoarthritis (strongest evidence), postmenopausal women (bone/hormonal support), anyone with suboptimal vitamin D status, chronic inflammatory conditions. Evidence is moderate — multiple small RCTs, no meta-analyses.

Emerging paradigm (2024–2026): The Scorei/Bita group proposes boron as a microbiota-dependent essential nutrient via "boron symbiotaxis" — boron stabilizes AI-2 quorum sensing signals in the gut microbiome. Still theoretical with testable predictions, zero human trials.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7–9=strong causal | 5–6=moderate | 3–4=weak | 1–2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication Star legend: 5/5 Multiple large RCTs + MA | 4/5 Several human RCTs | 3/5 Some human pilot data | 2/5 Animal/very limited human | 1/5 None/debunked

Prescribing

Dosing Table

Average dietary intake: US adults 0.87–1.35 mg/d; vegetarians 1.5–3 mg/d. Not classified as essential — no RDA/AI. WHO safe range: 1–13 mg/d. No loading protocol needed; steady-state reached quickly. No cycling necessary — continuous use is optimal (homeostasis via renal excretion, no tolerance development).

Formulation Table

All forms hydrolyze to boric acid in the GI tract. Bioavailability is uniformly high (85–90%) regardless of form — the choice is driven by clinical evidence (CaFB has the most), cost, and elemental boron content, not absorption differences. Absorbed via passive diffusion; no CYP450 metabolism; peak plasma 1–4h; >90% urinary excretion.

Condition-Specific Protocols

Osteoarthritis Protocol

Evidence: 4/5 | PMIDs: 7889887, 24940052, 21607703

Phase 1: Initiation (Weeks 1–2)

• CaFB 6 mg/d elemental boron with food
• Baseline: CRP, ESR, kidney function (creatinine/GFR)
• Continue current analgesics; do not discontinue NSAIDs

Phase 2: Therapeutic (Weeks 3–8)

• Maintain 6 mg/d; assess pain/stiffness at week 4
• If inadequate response: consider 12 mg/d (used in one study — monitor closely)
• Monitor CRP at week 4 and week 8

Phase 3: Maintenance (Week 8+)

• Continue 6 mg/d indefinitely if beneficial
• Annual kidney function check if >65 or GFR borderline
• May reduce NSAID use if symptoms improve

Expected Outcomes: Pain ↓ and stiffness ↓ within 2–8 weeks; CRP reduction 23–88% within 1–2 weeks Stop/Reassess Criteria: No improvement after 8 weeks at 6 mg/d → discontinue; rising creatinine → stop

Safety

Interactions Table

No CYP450 interactions. No significant protein binding. No interference with standard drugs at supplement doses (1–10 mg/d). No known interactions with statins, ACE inhibitors, beta-blockers, anticoagulants, methotrexate, biologics, or levothyroxine.

Contraindications

• Absolute: Severe renal impairment (GFR <30) — accumulation risk; known hypersensitivity to boron compounds
• Relative: Moderate renal impairment (GFR 30–60) — reduce dose, monitor; pregnancy/lactation — insufficient safety data; pediatric — no efficacy/safety data

Adverse Effects

At recommended doses (1–10 mg/day): very well tolerated. Therapeutic index is very wide (therapeutic 3–6 mg → toxic >500 mg).

Toxicity thresholds: Acute >500 mg (nausea, vomiting, diarrhea). Chronic >20 mg/d long-term (reproductive effects, animal data). Lethal ~15,000–20,000 mg. No dependence or withdrawal. GRAS regulatory status.

FAERS Signal Table

FAERS interpretation: 454 reports (as "boron") + 538 (as "boric acid") = 992 total. Most are concomitant-drug reports alongside actual suspect drugs (denosumab, adalimumab, lenalidomide). The "boric acid" profile shows uniform ~110–131 counts across unrelated reactions — hallmark of a single large case series submission, not independent signals. Top co-reported drugs (methotrexate, prednisone, ibuprofen) indicate RA patients. No credible safety signal for oral boron supplementation.

Monitoring Table

Special Populations

Renal Impairment

Hepatic impairment: No adjustment needed — boron is not hepatically metabolized. Excreted unchanged in urine.

Pregnancy & Lactation

No controlled human studies. Animal data: high-dose boron (toxic levels) caused developmental effects. Breast milk contains 0.27 mg/L boron. Dietary intake (1–1.08 mg/d) appears safe. Avoid supplementation; dietary sources adequate.

Autoimmune Caution (NEW — 2025)

Human ex vivo data (PMID: 39446208) shows mixed results: in healthy controls, boric acid improved Treg/Th17 ratio (beneficial). In RA/SLE patients, BA and CaFB increased Ror-γ-t (pro-Th17 — potentially harmful). Low-dose BA decreased TNF-α in RA. Use with caution in autoimmune disease; anti-inflammatory benefit may be offset by Th17 shift.

Synergies & Stacking

Recommended bone health stack: Boron 3–6 mg/d + Vitamin D3 1000–2000 IU/d + Calcium 1000–1200 mg/d + Magnesium 300–400 mg/d + Vitamin K2 100–200 μg/d

No known antagonistic interactions with other nutrients. Boron does not share absorption pathways with other minerals — no competitive inhibition.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No CYP450 involvement (boron is not CYP-metabolized). No boron-specific transporter polymorphisms identified. No pharmacogenomic studies exist. Future research may identify genetic variation in boron transporters or hormone receptors.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Positive-to-mixed across ~500+ reports (Reddit r/Supplements, r/Nootropics, r/Peptides; Longecity; ExcelMale; Earth Clinic; WebMD reviews).

What Users Report

Notable absences: No community reports of vision changes, blood sugar effects, cardiovascular benefits, immune function changes, or gray hair reversal.

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: No significant MLM companies push boron specifically
• Influencer concentration: Moderate — several YouTube biohackers cite the N=8 Naghii study while ignoring the N=19 negative Ferrando RCT
• Astroturfing signals: Minimal for standard supplements; borax/Earth Clinic community has evangelical characteristics but appears organic (no commercial driver)
• Commercial bias: Scorei group (Romania) has connections to FruitEx-B/calcium fructoborate products — potential bias in CaFB studies
• Borax protocol danger: The viral TikTok/Earth Clinic protocol uses cleaning-grade sodium borate at doses exceeding the UL. Poison control centers have issued warnings. Primary safety concern in community space.

Folk vs Clinical Reality Check

Community experience aligns with clinical data on joint pain/stiffness improvement — the most consistently reported benefit across both domains. Community experience diverges on testosterone: the N=8 Naghii study gets amplified while the larger negative RCT (Ferrando, N=19) is systematically ignored. The perceived testosterone/libido boost likely reflects placebo effect and confirmation bias. The borax protocol represents a genuine safety concern with no clinical support for extreme doses used.

Copper interaction note (Longecity): Users report boron may increase serum copper with long-term high-dose use. Not confirmed clinically but warrants monitoring if using >6 mg/d long-term.

Japan market note: Boron marketed to women for bust enhancement via estrogen activation — debunked as pseudoscientific by Japanese clinics. Korean market is more conservative and measured.

Deep Dive: Mechanisms & Research

Key Mechanisms (Ataraxia-vetted)

Clinical translation confirmed:

• Anti-inflammatory cytokine modulation: NF-κB pathway inhibition → CRP ↓23–88%, TNF-α ↓, IL-6 ↓. Replicated in multiple human studies.
• Mineral retention: Reduces urinary calcium and magnesium excretion. Directly measured in metabolic studies.
• Steroid hormone modulation: Increases serum estradiol and testosterone in postmenopausal women. Mechanism unclear — possibly 24-hydroxylase inhibition or SHBG modulation.

Clinical translation partial:

• 24-Hydroxylase (CYP24A1) inhibition: Proposed vitamin D sparing mechanism. Strong animal data; limited human confirmation.
• Osteoblast/osteoclast regulation: Animal data shows improved bone microarchitecture. No direct human BMD endpoint data.

Preclinical only (hypothesis-generating, 2024–2026):

• Gut microbiome — "boron symbiotaxis": Boron stabilizes AI-2 quorum sensing signals. Mouse data shows ↑Lactobacillus, Bifidobacterium. MABCs (microbiota-accessible boron complexes) proposed as novel prebiotics. Zero human data. (PMIDs: 41568046, 39458975, 41463367, 40573163)
• Neuroprotection/Alzheimer's: Reduces amyloid/tau markers, oxidative stress in animals. Deprivation impairs human cognition but supplementation benefit in non-deficient not demonstrated. Borolatonin (boron-melatonin conjugate) shows promise in female rats. (PMIDs: 39515586, 38423984)
• Anti-adipogenic: CaFB inhibits adipogenesis via PPARγ/SIRT pathway in vitro. (PMID: 39531139)
• Inflammaging/senescence: NaB attenuated p16/p21 senescence markers in aging rat model. First preclinical aging data. (PMID: 41740231)
• Treg/Th17 modulation: Healthy controls → improved Treg/Th17 ratio. RA/SLE patients → unexpectedly increased Ror-γ-t (pro-Th17). Caution in autoimmune disease. (PMID: 39446208)
• Hepatoprotection: Consistent protective signal across cyclophosphamide, alcohol, cholestasis models. (PMIDs: 39416834, 40345014, 40399695)
• Cancer (preclinical): BA/NaB anti-cancer effects in colorectal, glioblastoma, endometrial, NSCLC, HCC cell lines. Zero human data. (PMIDs: 37770673, 39821858, 40872562)
• CaFB OA mechanism: Hedgehog/DDIT3 pathway activation, cartilage protection in rat MIA model. (PMID: 39572483)

Clinical Trials (from ClinicalTrials.gov)

Most registered trials are for Boron Neutron Capture Therapy (BNCT) — irrelevant to oral supplementation. The oral supplementation landscape is thin: no Phase 3 RCTs for oral boron, largest registered trial (N=300 CaFB) has unknown status. No Cochrane review. No human systematic review/meta-analysis for oral supplementation.

Regulatory Status

• FDA: Not approved as drug. Dietary supplement under DSHEA. GRAS for food use. UL: 20 mg/d adults (IOM 2001, NOAEL 9.6 mg/kg/d in rats, UF 60).
• EFSA: UL: 10 mg/d adults (more conservative; reaffirmed 2024). Age-scaled: 3 mg (1–3y), 7 mg (4–6y), 9 mg (7–10y), 10 mg (11+).
• WADA: Not prohibited; safe for competitive athletes.
• Regulatory context: Boron has never been submitted for drug approval. Cheap, non-patentable trace mineral with no commercial incentive for pharma development. "Not approved" reflects business economics, not safety concerns.

Ataraxia Verdict (as of 2026-04-15)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to nature: "It's a trace mineral found in fruits" → used to imply necessity. Boron is NOT classified as essential. (MEDIUM)
• Hasty generalization: Bone health claims extrapolate heavily from animal studies. Direct human BMD evidence is missing. (HIGH)
• Cherry-picking: Naghii 2011 (N=8, testosterone ↑) widely cited by supplement marketers. Ferrando 1993 (N=19, no effect) systematically ignored. (HIGH)
• Appeal to authority: Nielsen/Hunt group (USDA) dominates early literature — single research group over-reliance. (MEDIUM)
• Ecological fallacy: "Areas with low soil boron have more arthritis" — does not prove supplementation helps. Confounded by diet, SES, climate. (MEDIUM)

Evidence Gaps

1. No meta-analyses exist for any boron indication
2. No large RCTs (>100) for primary bone or OA outcomes
3. No direct BMD or fracture endpoint trials in humans
4. No long-term safety data (>2 years)
5. No dose-response studies — optimal dose unknown
6. No head-to-head formulation comparisons (CaFB vs borate vs chelates)
7. No pediatric or pregnancy safety data
8. No pharmacogenomic data — boron transporter genetics unexplored
9. Gut microbiome paradigm ("boron symbiotaxis") has zero human trials despite being the biggest theoretical advance (2024–2026)
10. Nobody has replicated Nielsen's 1987 postmenopausal hormone work in nearly 40 years

Bias Flags (Mode 4: First Principles)

• What survives scrutiny: CRP reduction (replicated), OA symptom improvement (multiple small RCTs), calcium/magnesium retention (metabolic studies)
• What doesn't: Testosterone boost in young men (debunked), cognitive enhancement in non-deficient (never demonstrated), cancer prevention (ecological fallacy)
• Dosing basis: 3–6 mg/d from human RCTs. This is solid.
• Cui bono: Supplement industry benefits from testosterone claims. FruitEx-B has commercial interest in CaFB-specific studies. Overall, boron is a low-profit supplement with modest commercial pressure.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Primary manipulation = testosterone claims. Bodybuilding supplement companies market boron as "natural testosterone booster" despite the negative Ferrando RCT. Exploits male insecurity about aging/hormones.
• Influencer economics: Moderate hype. Several biohacker YouTubers promote boron for testosterone. Not as influencer-driven as turkesterone, tongkat ali, etc.
• Counter-narrative manipulation: Minimal. Boron is too cheap/niche to attract organized FUD campaigns.
• Cui bono summary: Pro: FruitEx-B (CaFB manufacturer), generic supplement companies. Anti: no significant opponents.
• Red team highlight: The Scorei group's CaFB studies are the strongest OA evidence, but the same group has commercial ties to CaFB. Independent replication is needed. This is the single most concerning angle.

Decision Support (Mode 3: Clarity Compass)

• General health utility: 6/10. Cheap, safe, anti-inflammatory, bone-supportive. Nice-to-have, not essential.
• Opportunity cost: Minimal — $5–25/month, almost no side effects, no complex interactions.
• Verdict: CONDITIONAL
• Conditions: ADD if: (1) osteoarthritis or chronic joint pain, (2) postmenopausal bone health concern, (3) suboptimal vitamin D status despite supplementation, (4) chronic inflammatory markers elevated. WATCH for general population without specific indication. SKIP for testosterone optimization (evidence debunked).

Bottom Line

Boron is a cheap, safe, modestly effective anti-inflammatory trace mineral with strongest evidence in osteoarthritis symptom reduction (as calcium fructoborate, 6 mg/d). Bone health rationale is plausible but rests on surrogate markers — no human has ever demonstrated BMD improvement from boron. Testosterone claims are marketing noise contradicted by the only relevant RCT. The emerging gut microbiome paradigm is theoretically exciting but entirely preclinical. At $5–25/month with virtually no downside risk, boron earns a conditional recommendation for specific populations but does not justify universal supplementation.

Practical Notes

Brands & Product Selection

Quality markers: third-party testing (USP, NSF, ConsumerLab), ≥99% purity, heavy metal testing (<5 ppm), clear elemental boron content on label, cGMP facility, batch/lot numbers. Red flags: proprietary blends, "massive testosterone boost" claims, no testing, no manufacturer contact.

Notable brands (not endorsements — verify current certification): Thorne (boron glycinate, NSF), Pure Encapsulations (glycinate), NOW Foods (various, USP select), Life Extension (bone formulas), Futurebiotics (CaFB).

Storage & Handling

Room temperature (15–25°C), away from direct sunlight and moisture. Boron compounds are stable but hygroscopic. Shelf life 2–3 years unopened, 18–24 months opened. Keep tightly sealed; not in bathroom cabinet.

Palatability & Compliance

Capsules/tablets recommended. If using powder: CaFB is relatively tasteless; sodium borate is mildly salty/alkaline. Single daily dose is optimal for compliance — split dosing unnecessary.

Exercise & Circadian Timing

No circadian preference. Not stimulating or sedating. No acute performance benefit. Chronic use may support bone adaptation over months. Take whenever most convenient for routine.

Reference Ranges (Expected Biomarker Changes)

Cost

Cost-effectiveness winner: sodium borate. Best value for evidence: CaFB.

What We Don't Know

• Whether boron supplementation directly improves BMD or reduces fracture risk (all evidence is surrogate markers)
• Optimal dose for any indication (no dose-response studies exist)
• Long-term safety beyond 2 years in humans
• Whether the gut microbiome paradigm ("boron symbiotaxis") translates to humans
• Whether CaFB is genuinely superior to sodium borate, or just better-studied
• Genetic factors affecting boron response (zero pharmacogenomic research)
• Safety in pregnancy, lactation, or pediatric populations
• Whether the Treg/Th17 shift in autoimmune patients is clinically relevant
• Whether boron's anti-inflammatory effects translate to cardiovascular outcomes
• Whether the N=300 CaFB joint health trial (NCT05438979) will ever report results
• Why nobody has replicated Nielsen's 1987 postmenopausal hormone work in nearly 40 years
• Whether the copper interaction reported on Longecity is real

References

Systematic Reviews & Guidelines

1. Pizzorno L. (2015). Nothing Boring About Boron. Integr Med 14(4):35-48. PMID: 26770156 — Comprehensive narrative review
2. Rondanelli M et al. (2020). Boron supplementation and bone health. J Trace Elem Med Biol 62:126577. PMID: 32540741 — Bone health review
3. Nielsen FH. (2014). Update on human health effects of boron. J Trace Elem Med Biol 28(4):383-387. PMID: 25063690 — Leading researcher update
4. Institute of Medicine (2001). DRIs for boron et al. National Academy Press. — UL 20 mg/d established
5. WHO (1998). Boron. Environmental Health Criteria 204. — Safe range 1–13 mg/d

Landmark Human RCTs

6. Newnham RE. (1994). Boron for bones and joints. Environ Health Perspect 102 Suppl 7:83-85. PMID: 7889887 — 6 mg/d, OA improvement, N=20
7. Nielsen FH et al. (1987). Dietary boron in postmenopausal women. FASEB J 1(5):394-397. PMID: 3678698 — 3 mg/d, hormonal changes, N=12
8. Scorei R et al. (2011). CaFB in OA — CRP and lipids. Biol Trace Elem Res 144:253-263. PMID: 21607703 — CRP ↓23%, N=60
9. Pietrzkowski Z et al. (2014). CaFB for knee discomfort. Clin Interv Aging 9:895-899. PMID: 24940052 — N=60
10. Ferrando AA, Green NR. (1993). No testosterone effect in bodybuilders. Int J Sport Nutr 3(2):140-149. PMID: 8508192 — 10 mg/d, null, N=19
11. Naghii MR et al. (2011). Boron, free testosterone, TNF-α. J Trace Elem Med Biol 25(1):54-58. PMID: 21129941 — 10 mg/d, N=8
12. Nikkhah S et al. (2015). Boron and dysmenorrhea. Complement Ther Clin Pract 21(2):79-83. PMID: 25906949 — N=113
13. Meacham SL et al. (1994). Boron in female athletes — no BMD change. Environ Health Perspect 102 Suppl 7:79-82. PMID: 7889886 — N=28
14. Hussain SA et al. (2016). CaFB + etanercept in RA. J Intercult Ethnopharmacol 5(2):148-152. PMID: 28163961 — N=38
15. Green NR, Ferrando AA. (1994). Plasma boron, no testosterone effect. Environ Health Perspect 102 Suppl 7. PMID: 7889885
16. Hunt CD et al. (1997). Postmenopausal boron metabolic responses. PMID: 9062533
17. Penland JG. (1999). Boron and brain function. Biol Trace Elem Res. PMID: 10050926 — Deprivation study
18. Aydin A et al. (2025). Kidney stone RCT — negative. PMID: 40792045 — 10 mg boron, N=60, no effect
19. Uslu E et al. (2025). Boric acid in periodontitis RCT. PMID: 40951753 — Topical 0.75%, N=36, positive
20. Akbari N et al. (2022). Boron citrate + OEA in COVID-19 pilot. PMID: 35183882

Mechanism & Animal Studies

21. Hegsted M et al. (1991). Boron in vit D-deficient rats. Biol Trace Elem Res 28(3):243-255. PMID: 1713047
22. Miljkovic D, McCarty MF. (2004). Boron and 24-hydroxylase. PMID: 15504575 — Vitamin D mechanism
23. Militaru C et al. (2013). Boron + resveratrol in angina. PMID: 23153742 — Lipid effects
24. Scorei ID et al. (2025). CaFB in OA rat model — Hedgehog/DDIT3. PMID: 39572483
25. Scorei ID et al. (2025). CaFB anti-adipogenic in vitro. PMID: 39531139
26. Tüzün A et al. (2024). Boron in diabetic rats. PMID: 37872360
27. Arpa MD et al. (2026). NaB anti-inflammaging in aging rats. PMID: 41740231
28. Özdemir S et al. (2024). Boron hepatoprotective. PMID: 39416834

New Paradigm: Gut Microbiome & Reviews (2024–2026)

29. Feng Y et al. (2024). Boric acid modulates gut microbiota in mice. PMID: 39458975
30. Bita CE et al. (2026). Boron symbiotaxis — AI-2 quorum sensing. PMID: 41568046
31. Bita CE et al. (2025). Dual-pathway boron bioavailability (MABCs). PMID: 41463367
32. Bita CE, Scorei IR. (2025). MABCs as prebiotics for longevity. PMID: 40573163
33. Das A et al. (2024). Boron retarding Alzheimer's. Review. PMID: 39515586
34. Doğan A et al. (2024). Boron in wound healing. Review. PMID: 39539690
35. Dinca L et al. (2026). Comprehensive review: Li, Si, B. PMID: 41683210

Autoimmune / Disease-Specific

36. Ucan B et al. (2025). BA/CaFB effects on Treg/Th17 in RA/SLE. PMID: 39446208 — Human ex vivo, mixed results